Nghiên cứu lâm sàng ngẫu nhiên Giai đoạn II về Hiệu quả và An toàn của Trastuzumab kết hợp với Docetaxel ở bệnh nhân ung thư vú di căn thụ thể HER2 dương tính được điều trị đầu tiên: Nhóm Nghiên cứu M77001
Tóm tắt
Từ khóa
#Trastuzumab #docetaxel #ung thư vú di căn #HER2 dương tính #nghiên cứu ngẫu nhiên #tỷ lệ sống sót #tỷ lệ đáp ứng #tiến triển bệnh #độc tính.Tài liệu tham khảo
Hynes N, Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165,1994-184,
Baselga J: Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials. Oncology 61:14,2001-21, (suppl 2)
Krasinska L, Jassem J: Taxanes in the treatment of advanced breast cancer. Nowotwory J Oncol 53:176,2003-184,
Kuzur M, Albain K, Huntington M, et al: A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER-2. Proc Am Soc Clin Oncol 19:131a,2000, (abstr 512)
Bauer-Kosińska B, Lemanska I, Glogowska I, et al: Efficacy and toxicity of docetaxel or cisplatin chemotherapy in combination with trastuzumab in the treatment of patients with chemotherapy pre-treated HER-2/neu overexpressed metastatic breast cancer. Eur J Cancer 1:S141,2003, (suppl 5; abstr 464)
Montemurro F, Choa G, Faggiuolo R, et al: Safety and activity of docetaxel and trastuzumab in HER2 overexpressing breast cancer: A pilot phase II study. Am J Clin Oncol 26:95,2003-97,
Tabei T, Kimura M, Sano M, et al: Multicenter phase II trial of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing metastatic breast cancer patients: Japan East Cancer Center Breast Cancer Consortium (JECBC 01 trial). Eur J Cancer 2:131,2004, (suppl 3; abstr 258)
Raab G, Brugger W, Harbeck N, et al: Multicenter randomized phase II study of docetaxel (Doc) given q3w vs q1w plus trastuzumab (Tra) as first line therapy for HER2 overexpressing adjuvant anthracycline pretreated metastatic breast cancer (MBC). Breast Cancer Res Treat 76:S114,2002, (suppl 1; abstr 443)
Meden H, Beneke A, Hesse T, et al: Weekly intravenous recombinant humanized anti-p185 monoclonal antibody (Herceptin) plus docetaxel in patients with metastatic breast cancer: A pilot study. Anticancer Res 21:1301,2001-1305, HER2
Takao S, Kohno N, Miyashita M, et al: Weekly docetaxel and trastuzumab for her2-overexpressing metastatic breast cancer: Efficacy and correlation with biological markers in a phase II, multicenter study. Eur J Cancer 2:137,2004, (suppl 3; abstr 280)
Theodoulou M, Campos SM, Batist G, et al: TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): Final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol 21:55a,2002, (abstr 216)
Baselga J, Climent MA, Lluch A, et al: Results of a phase II study of liposomal doxorubicin (Myocet) in combination with weekly paclitaxel and trastuzumab (Herceptin) in patientswith HER2-positive locally advanced or metastatic breast cancer (LA/MBC). Eur J Cancer 2:132,2004, (suppl 3; abstr 262)
Marty M, Baselga J, Gatzemeier U, et al: Pooled analysis of six trials of trastuzumab (Herceptin): Exploratory analysis of changes in left ventricular ejection fraction (LVEF) as a surrogate for clinical cardiac events. Breast Cancer Res Treat 82:S48,2003, (abstr 218)
Buzdar AU, Hunt K, Smith T, et al: Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab [Herceptin (H)], paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. Proc Am Soc Clin Oncol 23:7,2004, (abstr 520)